key: cord-0736260-s9wpyfst authors: Sarkar, R.; Chawla-Sarkar, M.; Majumdar, S.; Lo, M.; Chattopadhyay, S. title: Geographical and temporal distribution of SARS-CoV-2 globally: An attempt to correlate case fatality rate with the circulating dominant SARS-CoV-2 clades date: 2021-05-27 journal: nan DOI: 10.1101/2021.05.25.21257434 sha: 1c1571ee01987e8637de3be6f66116c262cba2d8 doc_id: 736260 cord_uid: s9wpyfst Uncontrolled high transmission is driving the continuous evolution of SARS-CoV-2, leading to the nonstop emergence of the new variants with varying sensitivity to the neutralizing antibodies and vaccines. We have analysed of 8,82,740 SARS-CoV-2 genome sequences, collected and sequenced during late December 2019 to 25 March 2021 from all across the world. The findings revealed differences in temporal and spatial distribution, and predominance of various clades/variants among six different continents.We found no clear association between the pathogenic potential of the various clades by comparing the case fatality rate (CFR) of 170 countries with the predominant SARS-CoV-2 clades in those countries, demonstrating the insignificance of the clade specific mutations on case fatality. Overall, relying on a large-scale dataset, this study illustrated the time-based evolution and prevalence of various clades /variants among different geographic regions. The study may help in designing continent specific vaccines in the future. The novel coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late December, 2019 in the city of Wuhan, China. As of 31March, 2021, about one year since the pandemic was declared, the disease had spread to 221 countries across the world, infecting around 132 million people and causing2.8 million casualties (https://www.worldometers).Since its eminence, the virus has been continuously evolving by procuring new mutations which may also be a crucial factor in driving rapid transmission and governing severity of the disease. Notably, the nature of pandemic's progression and the case fatality rate (CFR) vary among different countries. This is possibly due to difference in demographic composition of the population, the government policies to mitigate transmission of the disease and most importantly the pathogenic potential of different SARS-CoV-2 clades (Forster et al., 2020) . Phylogenetic studies, till early March, 2020, reported the emergence of three different clades of SARS-CoV-2 namely A, B and C (Mercatelli et al., 2020) , which were subsequently named L, S and V clade respectively by the Global Initiative on Sharing All Influenza Data (GISAID) (https://www.gisaid.org/). With the progression of the pandemic, five more different clades (Clade G, GH, GR, GV and O according to GISAID nomenclature) having specific set of novel coexisting mutations emerged and predominated until December 2020. The G clade is characterized by the presence of four coexisting mutations 241C>T in 5'-UTR, F106F (3037C>T) in NSP3, P323L (14408C>T) in RdRp and D614G (23403A>G) in S glycoprotein; whereas the GH, GR and GV clades have additional Q57H (25563G>T) in ORF3a, RG203KR (28881GGG>CCA) in N protein, and A222V (22227C>T) in S glycoprotein respectively Ceraolo et al., 2020) . The missense mutation L84S (28144T>C) in ORF8 and the silent mutation S76S in NSP4 (8782C>T) are the signature mutations of the S clade (Brufsky et al., 2020) . The V clade is distinguished by the hallmark mutations G251V (26144G>T) in ORF3a and L37F (11083G>T) in NSP6 (Mercatelli et al., 2020) . The first emerging L clade carries the reference alleles for all the loci defined in the G, GH, GR, GV, S, O and V clades. Genome sequences not matching the mutational criteria of above mentioned six clades are considered as the O clade . Emerging SARS-CoV-2 variants with evidence of increased transmissibility, increased severity, reduced sensitivity to neutralizing antibodies and reduced vaccine-induced protection were termed "variants of concern" (VOCs) by CDC (https://www.cdc.gov). At the transition of 2020-2021 four VOCs emerged, each with several mutations throughout the genome, including the S gene, and rapidly predominated globally. The VOC202012/01 (Variant of Concern, year 2020, month 12, variant 01) (also known as B.1.1.7 or 20I/501Y.V1 or GRY or UK variant) contains 17 lineage defining non-synonymous mutations, including the D614G mutation and 8 additional mutations in Spike glycoprotein: ΔH69-V70, ΔY144, N501Y, A570D, P681H, T716I, S982A, and D1118H (Rambaut et al., 2020 , Wang et al., 2021 . The VOC B.1.351 (also known as 20H/501Y.V2 or South African variant) had 9 spike mutations in addition to D614G, including a cluster of mutations (Δ242-244&R246I) in NTD, three mutations (K417N, E484K, & N501Y) in RBD, and one mutation (A701V) near the furin cleavage site (Tegally et al., 2020; Wang et al., 2021) . The VOC P.1 (also known as Brazilian variant or 20J/501Y.V3 or B.1.1.248) encompasses 10 spike mutations in addition to D614G, including three mutations (K417N/T, E484K, and N501Y) in the receptor-binding domain (RBD), five mutations (L18F, T20N, P26S, D138Y and R190S) in the N-terminal domain (NTD), and H655Y near the furin cleavage site (Faria et al., 2021; Sabino et al., 2021) . The VOC P.1.427/429 (also known as California variant or 20C/S:452R) holds five mutations in addition to D614G, including three mutations (S13I; W152C; L452R) in spike protein, one in OFR1a (I4205V) and one in OFR1b (D1183Y) . High transmissibility or infection rate of SARS-CoV-2 had enabled the virus to acquire continuous mutations, having the potential to give enhanced fitness, that lead to the emergence of multiple clades despite being low evolutionary rate of SARS-CoV-2 (~0.8 x10 -3 substitutions per site per year) compared to other RNA viruses (Day et al., 2020; Fontanet et al., 2021) . Several studies have been attempted to uncover the relevance of gained mutations in the context of viral spread and immune invasion. Primary importance was given to spike protein mutations because this glycoprotein is involved in receptor binding and entry into the host cell, and is also the prime target for neutralizing antibodies (Ou et al., 2020; Piccoli et al., 2020) . Several studies have claimed the role of D614G mutation of spike protein in amplified infectivity in vitro (Korber et al., 2020; Hou et al., 2020) , enhanced spread in hamsters (Hou et al., 2020 ) and a mild escalation in neutralization susceptibility (Weissman et al., 2020) , all of which were demonstrated by D614G induced more open conformation of the receptor binding domain (RBD) of the spike protein (Yurkovetskiy et al., 2020) .The A222V mutation of S glycoprotein, which is present within the B cell immuno-dominant epitope, has also been linked with the reinfection of SARS-CoV-2 (Ceraolo et al., 2020) .The functional relevance of mutations acquired within the nonstructural and structural proteins except spike protein remains largely undetermined. Though, recent studies have claimed the role of L37F mutation of NSP6 in asymptomatic infection based on clinical data (Aiewsakun et al., 2020; Wang et al., 2020) . Therefore, the overall pathogenic potential and/or transmissibility of SARS-CoV-2 could be influenced by cumulative effect of all the mutations selected in different genes throughout the genome. It is still unclear whether the difference in case fatality rate and speed of disease transmission among different countries are due to discrepancy in the pathogenic potential of different clades or variants. In the present study, we provided a snapshot of geographical and temporal distribution of different clades all across the world to give a better understanding of the gradual emergence and predominance of different clades/variants over time. We also attempted to evaluate the pathogenic potential of different clades by correlating the case fatality rate of 170 countries with the SARS-CoV-2 clades that were prevalent in those countries. Materials and Methods 2.1. In total, we analyzed 8,82,740SARS-CoV-2 genome sequences, that were collected during late December, 2019 to 25 March, 2021 from all across the world, available at the global initiative of sharing all influenza data (GISAID) (https://www.gisaid.org/) (Shu et al., 2017) . Distribution of different clades of SARS-CoV-2among various continents and associated countries were analyzed by using "Location" and "Clade" specific filters offered by GISAID database, whereas temporal distribution of different clades/variants was analyzed by using "Location", "Collection Date" and "Clade/Variant" specific filters. First isolated SARS-CoV-2 strains of different clades/variants from six different continents were identified by initially sorting sequences using "Location" and "Clade/variant" specific filters and then analysing the first collection date. We have accessed WHO site (https://covid19.who.int/) on 25 March, 2021 to compile the total number of reported COVID cases and confirmed COVID deaths in various countries. Then, case fatality rate (CFR) of each country was calculated by using the formula: (Total number of COVID deaths/Total number of confirmed COVID cases) X 100. In the present study, we have analyzed 8, 82, 740 Table 1) . Geographical root monitoring based on first collection date and month wise frequency distribution of different clades revealed the first detection of the L clade (the first emerged clade) and the S clade in December 2019 at Wuhan of China. The V clade was first collected from China in January 2020. These three clades (L, S and V) surged in March 2020 and subsequently declined. In January 2020, the four clades (G, GH, GR and GV) emerged in Europe. The G clade was first detected in Germany whereas the GH, GR and GV clades were first detected in Netherlands. The G, GH and GR clades remained dominant from March 2020 to August 2020. The GV clade suddenly surged in September, 2020 and dominated over G, GH and GR clades until December, 2020. Though, we found the first appearance of the B.1.1.7 or UK variant in Spain in February 2020, B.1.1.7 continued to surge from October 2020 and dominated worldwide from January 2021 to March 2021. Initial emergence of the B.1.427/429 or California variant was seen in Mexico in July, 2020 followed by continuous increase in frequency from November 2020. After initial detection in South Africa in October 2020, the B.1.351 (South African variant) gradually spread out with the progression of time. The Brazilian variant (P.1) and the Nigerian variant (B.1.525) were first seen in Brazil and Nigeria respectively in December 2020, however no significant escalation in their frequencies were witnessed in the subsequent months ( Table 1, Table 2 , Figure 1C , Supplementary Table 2 ). Overall, we observed worldwide predominance of the GH clade in March 2020, the GR clade from April 2020 to September 2020, the GV clade from October 2020 to December 2020, and the UK variant from January 2021 to March 2021 ( Figure 1C ). The frequency distribution of various clades in Asia is different from the worldwide scenario. Asia was mostly predominated by the GR clade (28544, 59.45%) followed by GH ( Table 3 ). Temporal distribution presented that Asia has been consistently dominated by the GR clade, first observed in India among all the Asian countries in January 2020, since March 2020 to January 2021. In December 2020, the UK variant made its first appearance in India among Asian countries, and in February 2021, it became the dominant variant in Asia. The presence of the UK variant was detected in 24 of the 38 Asian countries studied. India, Israel, Japan, Jordan, Philippines, Singapore and South Korea all had considerably high incidence of UK variant. The South African variant and the California variant were first observed in Japan and South Korea respectively among Asian countries in December 2020, however, their occurrence remained very low throughout Asia in the following months, with the exception of the South African variant in Israel and the California variant in South Korea. In Asia, the Brazilian and Nigerian variants were first noticed in Japan and Jordan, respectively, and these mostly predominated in Japan. ( Figure 2B , Table 1 , Table 2 , Supplementary Figure 4 ). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2021. Overall, Africa was predominated by the GR clade (3377, 31.99%) followed by G (2716, 25 Altogether, North America was largely predominated by the GH clade (128115, 54.41%) followed by G (43647, Table 1 , Table 2, Supplementary Table 4 ). South America was mostly dominated by the GR clade (6087, 64.32%) followed by GH ( Table 3 ). Spatial and temporal distribution showed the predominance of the GR clade in South America since its first detection in Chile in February 2020 to February 2021, with highest occurrence in April 2020. The G and GH clades, which were first detected in Brazil in February and March 2020 respectively, peaked in frequencies in April and May of 2020, and then steadily declined in frequency until November 2020. The incidence of the G clade has risen suddenly since December, 2020 and became the predominant clade in South America in March, 2021. The Brazilian variant was first isolated from Brazil in December, 2020 and peaked in frequencies in January, 2021 and declined subsequently. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2021. Since its first emergence in December 2020, the UK variant has gradually increased in frequency ( Figure 5B , Figure 6A, Supplementary Figure 3) . Though, four clades G, GH, GR and GV were first isolated from Europe in January 2020 with respect to the global scenario, the GR clade predominated Europe until August 2020. The GV clade surged in frequency since August 2020 and dominated Europe from September 2020 to December 2020 with a steady rise in prevalence. The UK variant was first collected from Spain in February 2020, however, started to surge in frequency from December 2020 and dominated Europe from January 2021 to March 2021. The South African variant (First detected in Switzerland in November 2020), the Brazilian variant (First detected in Italy in January 2021), the California variant (First detected in England in December 2020) and the Nigerian variant (First detected in England in December 2020) remained very low in frequencies after their first detection ( Figure 6B , Table 1 , Table 2, Supplementary Table 4 ). All viruses are immensely potent in adapting to new hosts (Sanjuan et al., 2016) . Genotypic diversity among viruses occurs due to the accumulating mutations that might lead to various phenotypic changes in them. The continuous replacement of the branches in the tree of life (clade) is the key characteristic of biodiversity (Silvestro et al., 2015) . The viral biodiversity could be addressed by phylogenetic studies by analyzing the nucleotide/ amino acid homology (Das et al., 2021) . Clades are the monophyletic groups of organisms that share a common ancestor along with all its lineal descendants. Various viral clades are generated through the process of evolutionary pressure on host immunogenics (Tyor et al., 2013) . The study of the viral clades, which share sequence similarity and are descendants of a common ancestor can throw light on the evolutionary process. Different clades depict different extent of disease manifestation and pathological conditions. The host immunological determinants of disease severity are maximally gene-regulated (Kumar et al., 2020) . Evolution of viral genome facilitates it to evade the host immunity at times (DeDiego et al., 2008; Li et al., 2020) . Therefore, understanding the plethora of mutations in the viral genome leading to the clade-diversification could determine the importance of regulatory variation in evolution. Thorough study of the SARS-CoV-2 genomic mutations and characterizing them based on the clades from which they are derived can reveal the actual evolutionary history of the virus. The proclivity of disease severity depends upon the type of circulating virus clade in a particular geographical region and it causes different case fatality rates across different countries. Therefore, elucidation of the SARS-CoV-2 clades with temporal and spatial differences can underscore the evolutionary crosstalk amongst them. The process of natural selection maximally determines the dynamics of an emerging mutation. The variants resulting due to mutations that impart a competitive and selection advantage in context to viral replication, transmission, or evasion of immune response will upsurge and eventually outcompete all other circulating variants. Though, other potential factors like chronic infection among immuno-compromised subjects, change of host-reservoirs, chance-events, faulty proof-reading mechanisms in the virus could be potential drivers of viral evolution. Based on the large-scale genome dataset of SARS-CoV-2, our present study depicted the global as well as continent wise emergence and prevalence of various clades/ variants as the COVID-19 pandemic progressed from its beginning in December 2019 to March 2021. Cryo EM analyses by some researchers reveal that the N501Y mutation found among the preponderant SARS-CoV-2 UK variant (B.1.1.7) highly increases viral infectivity (Zhu et al., 2021) . This is at par to the observation of our study where the total frequency distribution showed the global predominance of the UK variant (24.3%), currently. The UK variant possesses the characteristic feature of high transmission ability, contributing to an upsurge in the number of positive cases and hospitalizations worldwide. This is imposing an immense pressure on the health care system, especially during the second wave of the pandemic. Epidemiological surveillances and computational modelling underscore that the SARS-CoV-2 UK variant spreads 56% faster than pre-existing variants, resulting in higher nasopharyngeal viral titer compared to the prototype strain (Davies et al., 2021a) . Studies estimate a 35% (12-64%) increased risk of death associated with this highly transmissible UK variant, indicating that it can cause serious disease manifestation, though there is no confirmatory evidence of this variant causing severity among children (Davies et al., 2021b; Brookman et al., 2021) . It is not evident how this B.1.1.7 achieved prominence, although the unusual genetic divergence of the B.1.1.7 lineage may have resulted, at least in part, from the evolution of the virus in an individual with chronic infection (Rambaut et al., 2020) . Surveillance studies revealed the upsurge in SARS-CoV-2 clades harbouring the D614G mutation with the predominance of the clade GV during the last three months, which is consistent to our results. Our results underscored the temporal preponderance of mostly the GR clade, followed by others like GH, GR, GV and UK variant. As per Hamed et. al., 2021 , among all the currently circulating SARS-CoV-2 clades, GR predominated worldwide, subsequently followed by GV and GH clades. Severe or deceased COVID-19 patients were more susceptible to the GH and GR clades, while the asymptomatic/ mildly symptomatic individuals revealed a higher frequency of G and GV clades (Hamed et al., 2021) . However, it will be worth noting that due to the recent outbreak of pandemic COVID-19, people around the world are trying by every means to reach the origin, to get some ways of prevention and therapeutic pathways. Constant global monitoring of the SARS-CoV-2 clades and variants will help in tracking viral evolution. G and G-derived clades had been reported from North America and Asia in March 2020 and are currently the predominating viral subpopulation, globally (Mercatelli et al., 2020) . Other in silico studies also reported the diversity of SARS-CoV-2 infection in ten Asian countries which focused on the prevalence of clades such as G, GH, GR, L, S, O, and V . The geographical distribution of Nextstrain and GISAID clades revealed that clade 19B/S prevailed rarely, except in Spain and Kazakhstan, while the frequencies of the rest of the clades varied across the other countries in the WHO European Region (Alm et al., 2020) . Even the Eastern Mediterranean Region countries reported the dominance of G, GH and GR clades (Omais et al., 2021) . Through this study, we observed an upsurge of G clade strains along with its derivatives like the GH and GR clades; while clades L and V eventually diminished. Across the United States and Spain, clade S, though declined, nevertheless can be seen sporadically. During the first wave of the pandemic in 2020, a study revealed that the clade with variants ORF1ab L3606F, A4489V, S2015R, T2016K, and N P13L is common to Singapore which had been attributed to the low case fatality rate of Singapore (Koyama et al., 2020) . Another study analyzed SARS-CoV-2 genomic sequences from Eastern Mediterranean Region countries and revealed no association between increased CFR and the G, GH and GR clades (Omais et al., 2021) . A study from Washington also showed that no significant difference exists in the rates of hospitalization or death due to the predominating two clades in that region. Major risk factors for hospitalization and death for either major clade of virus include patient age and comorbid conditions (Nakamichi et al., 2021) . In consistent with the studies by Omais et al., 2021 and Nakamichi et al., 2021 , our current analysis has not found any correlation among the prevalence of a particular clade and its association to high CFR in that particular geographical area. Few clades and variants might have high infectivity, but studies in terms to their lethality are limited to date. Therefore, the differences in case fatality rate among different countries could be regulated by several factors including comorbidity risk and demographic, economic and political factors (Sorci et al., 2020) . In order to design the preventive measures and therapeutic approaches, tracing the evolutionary and phylogenetic history of SARS-CoV-2 is the need of the hour. Dissecting out the viral genomic diversity, clinical manifestations in conjunction with epidemiological surveillance data will certainly prove beneficial in chalking out avenues to overcome the disease burden.SARS-CoV-2 is continuing to mutate and evolve, leading to the emergence of differential genomic sequences, with higher infectivity, lethality along with clinical and pharmacological repercussions.To date, limited studies have been done to elucidate and compare the genomic, molecular and phenotypic differences between the various circulating clades of SARS-CoV-2.The current study has shed enough light on the clade-wise temporal and spatial analyses across all the 6 continents, globally. This study underscores the dynamicity of the different viral clades, which can lead to personalized/ customized prevention and treatment strategies for each geographical region depending on the circulating clade. content. SC conceived the study, supervised data analysis, provided scientific inputs and edited the draft manuscript. Authors declare no conflict of interest This research did not receive any specific grant from funding agencies in the public, commercial or not-for profit sectors. 38. Omais, S.O., Kharroubi, S.O. and Zaraket, H., 2021. No association between the SARS-CoV-2 variants and mortality rates in the Eastern Mediterranean Region. medRxiv. 39. Koyama, T. and Parida, L., 2020. Identification of a low pathogenicity clade of SARS-CoV-2. 40. Nakamichi, K., Shen, J.Z., Lee, C.S., Lee, A., Roberts, E.A., Simonson, P.D., Roychoudhury, P., Andriesen, J., Randhawa, A.K., Mathias, P.C. and Greninger, A.L., 2021. Hospitalization and mortality associated with SARS-CoV-2 viral clades in COVID-19. Scientific reports, 11 (1), pp. 1-11. 41 . Sorci, G., Faivre, B. and Morand, S., 2020. Explaining among-country variation in COVID-19 case fatality rate. Scientific reports, 10 (1), pp.1-11. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 27, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 27, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 27, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Phylogenetic network analysis of SARS-CoV-2 genomes Geographic and Genomic Distribution of SARS-CoV-2 Mutations Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020 Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing Genomic variance of the 2019-nCoV coronavirus Distinct Viral Clades of SARS-CoV-2: Implications for Modeling of Viral Spread Preliminary genomic characterisation of an emergent SARSCoV-2 lineage in the UK defined by a novel set of spike mutations Antibody resistance of SARS-CoV-2 variants B. 1.351 and B Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. Virological Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence Emergence of a novel SARS-CoV-2 variant in Southern California On the evolutionary epidemiology of SARS-CoV-2 SARS-CoV-2 variants and ending the COVID-19 pandemic Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptorbinding domain by structure-guided high-resolution serology Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo D614G spike mutation increases SARS CoV-2 susceptibility to neutralization Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant SARS-CoV-2 genetic variations associated with COVID-19 severity Decoding asymptomatic COVID-19 infection and transmission GISAID: Global initiative on sharing all influenza data-from vision to reality Mechanisms of viral mutation. Cellular and molecular life sciences The role of clade competition in the diversification of North American canids Mapping sequence to feature vector using numerical representation of codons targeted to amino acids for alignment-free sequence analysis Effect of HIV clade differences on the onset and severity of HIV-associated neurocognitive disorders The rise and impact of COVID-19 in India Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice The divergence between SARS-CoV-2 and RaTG13 might be overestimated due to the extensive RNA modification Cryo-EM Structure of the N501Y SARS-CoV-2 Spike Protein in Complex with a Potent Neutralizing Antibody. BioRxiv Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern Effect of the new SARS-CoV-2 variant B. 1.1. 7 on children and young people Global dynamics of SARS-CoV-2 clades and their relation to COVID-19 epidemiology Clade GR and clade GH isolates of SARS-CoV-2 in Asia show highest amount of SNPs Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region South Africa/GP hCoV-19/South Africa/R02827 South Africa / Eastern Cape hCoV-19/South Africa/N00390 North America Clade Collection date Location Accession South America Clade Collection date Location Accession Gerais Brazil/Sao Paulo Brazil/Rio de Janeiro hCoV-19/Brazil/MG GV Not Australia hCoV-19/Australia